KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) FCF Margin (2017 - 2025)

Amneal Pharmaceuticals has reported FCF Margin over the past 9 years, most recently at 13.33% for Q4 2025.

  • Quarterly results put FCF Margin at 13.33% for Q4 2025, down 76.0% from a year ago — trailing twelve months through Dec 2025 was 8.94% (up 24.0% YoY), and the annual figure for FY2025 was 8.94%, up 24.0%.
  • FCF Margin for Q4 2025 was 13.33% at Amneal Pharmaceuticals, down from 13.53% in the prior quarter.
  • Over the last five years, FCF Margin for AMRX hit a ceiling of 27.65% in Q1 2021 and a floor of 23.34% in Q2 2022.
  • Median FCF Margin over the past 5 years was 12.29% (2023), compared with a mean of 8.23%.
  • Biggest five-year swings in FCF Margin: tumbled -4790bps in 2021 and later skyrocketed 2612bps in 2023.
  • Amneal Pharmaceuticals' FCF Margin stood at 8.52% in 2021, then plummeted by -167bps to 5.7% in 2022, then skyrocketed by 458bps to 20.42% in 2023, then tumbled by -31bps to 14.09% in 2024, then fell by -5bps to 13.33% in 2025.
  • The last three reported values for FCF Margin were 13.33% (Q4 2025), 13.53% (Q3 2025), and 8.42% (Q2 2025) per Business Quant data.